SOURCE: Skystar Bio-Pharmaceutical

November 09, 2006 14:04 ET

Skystar Bio-Pharmaceutical Retains Nexus Investor Relations for Strategic IR Effort

XI'AN, CHINA -- (MARKET WIRE) -- November 9, 2006 -- Skystar Bio-Pharmaceutical (OTCBB: SKBI), a leading bio-pharmaceutical company in China, today announced that it has retained Nexus Investor Relations to lead an expanded shareholder communication program.

As investor relations counsel for Skystar Bio-Pharmaceutical, Los Angeles-based Nexus Investor Relations will raise investor awareness of the company's performance through a multi-channel campaign. Nexus IR will employ print and electronic media as well as direct communication with money managers and current and prospective shareholders. The Nexus IR program, focused on communicating Skystar Bio-Pharmaceutical's growth strategy within China, seeks both to broaden the company's shareholder base and to solidify the long term loyalty of current shareholders.

"We are pleased to have Nexus Investor Relations supporting our efforts to better communicate with our existing shareholders while simultaneously increasing our efforts to attract new investors to become familiar with our current robust expansion and our prospects for future growth," said Weibing Lu, Chief Executive Officer of Skystar Bio-Pharmaceutical. "The one crucial element we have lacked up to this point is a strong investor-relations program to raise our profile on Wall Street and give us better access to the capital markets should we require it. Our retention of IRI fills that gap, and we expect to benefit from much greater visibility and liquidity from here on."

If you would like to be added to Skystar Bio-Pharmaceutical's investor email list please contact Zack Noory with Nexus Investor Relations at

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China based producer and distributor of vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 60 state-of-the-art products with over 50 additional products in the developmental stage. One of the prominent products currently in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed strategic sales distribution networks in 27 provinces and regions throughout China. Skystar recently received China's State Ministry of Agriculture's authorization for the construction of a new Bio-Pharmaceutical facility, which will conform to Good Manufacturing Practices (GMP) standards and will significantly increase the company's production capacity. Skystar anticipates that this increase will help the company meet the overwhelming demand for its products.

About Nexus Investor Relations

Nexus Investor Relations, based in Los Angeles and serving a world wide client base, is a leading investor relations firm specializing in representing undervalued and under-followed companies with the objective of increasing their visibility on Wall Street, ultimately leading to increased shareholder value. Nexus IR represents companies trading on the Nasdaq National and Capital Markets, NYSE , AMEX and the Bulletin Boards. Nexus IR designs and implements customized investor relations programs to meet each client's unique needs.

Forward-looking statement: Except for the historical information, the matters discussed in this news release may contain forward-looking statements, including, but not limited to, factors relating to future sales. These forward-looking statements may involve a number of risks and uncertainties. Actual results may vary significantly based on a number of factors, including, but not limited to, uncertainties in product demand, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors detailed in the company's most recent annual report and other filings with the Securities and Exchange Commission.

Contact Information

    Scott Cramer
    Director - Investor Relations
    Email Contact

    Zack Noory
    Managing Partner
    Email Contact